Skip to main content
SpringerLink
Log in

Impact of dosage schedule of antibiotics on the treatment of serious infections

  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Experimental studies suggest that the importance of the antibiotic dosage schedule for therapeutic efficacy in severe infection and when host defences are impaired is related to the class of antibiotic. The efficacy of beta-lactams is mainly dependent on the maintenance of adequate antibiotic concentrations in plasma during the entire treatment interval, and not on high peak concentrations. The efficacy of aminoglycosides is related to the total dose administered, i.e., the area under the concentration-time curve, irrespective of the frequency of administration. This difference in efficacy between beta-lactams and aminoglycosides in relation to the dosage schedule correlate well with differences between both classes of antibiotics in kinetics of antibacterial activity in vitro and in vivo. Another factor relevant in this respect is the post-antibiotic effect (PAE) which means the suppression of bacterial regrowth at the end of the period of exposure to antibiotic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kunin CM (1981) Dosage schedules of antimicrobial agents: a historical review. Rev Infect Dis 3:4–11

    Google Scholar 

  2. Neu HC (1981) Current practices in antimicrobial dosing. Rev Infect Dis 3:12–18

    Google Scholar 

  3. Drusano GL (1988) Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 32:289–297

    Google Scholar 

  4. Gerber AU, Craig WA, Brugger HP, Feller C, Vastola AP,Brandel J (1983) Impact of dosing intervals on activity of gentamicin and ticarcillin againstPseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 147:910–917

    Google Scholar 

  5. Gerber AU, Brugger HP, Feller C, Strizko T, Stalder B (1986) Antibiotic therapy of infections due toPseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis 153:90–97

    Google Scholar 

  6. Gudmundsson S, Turnidge J, Craig WA (1982) Effect of different dosage regimens on in vivo efficacy of antibiotics againstKlebsiella pneumoniae. Clin Res 30:777A

    Google Scholar 

  7. Leggett JE, Fantin B, Ebert K, Totsuka K, Vogelman B, Calame W, Mattie M, Craig WA (1989) Comparative antibiotic-dose effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159:281–292

    Google Scholar 

  8. Roosendaal R, Bakker-Woudenberg IAJM, van den Berghe-van Raffe M, Michel MF (1986) Continuous versus intermittent administration of ceftazidine in experimentalKlebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 30:403–408

    Google Scholar 

  9. Roosendaal R, Bakker-Woudenberg IAJM, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF (1989) Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin inKlebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 8:878–887

    Google Scholar 

  10. Brugger HP, Gerber AU, Feller-Segessenmann C (1983) Bolusinjektion, Kurzinfusion oder Dauerinfusion von Aminoglycosid-Antibiotika? In-vivo-Studie mit Netilmicin andPseudomonas aeruginosa. Schweiz Med Wochenschr 113:1858–1860

    Google Scholar 

  11. Frimodt-Møller N, Thomsen VF (1987) Experimental pneumococus infection in mice: correlation of bactericidal activity in vitro with the effect in vivo for gentamicin, netilmicin and tobramycin. Acta Path Microbiol Scand Sect B 95:153–158

    Google Scholar 

  12. Gerber AU, Kozak S, Segessenman C, Flückiger U, Bangerter T, Greter U (1989) Once-daily versus thrice-daily administration of netilmicin in combination therapy ofPseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 8:233–237

    Google Scholar 

  13. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, Groden DL, Jacobs MR, DiScenna AO, Cash HA, Klinger JD (1983) Once-daily versus continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 147:918–932

    Google Scholar 

  14. Grasso S, Meinardi G, de Carneri I, Tamassia V (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13:570–576

    Google Scholar 

  15. Ingerman MJ, Pitsakis PG, Rosenberg AF, Levison ME (1986) The importance of pharmacodynamics in determining the dosing interval in therapy for experimentalPseudomonas endocarditis in the rat. J Infect Dis 153:707–714

    Google Scholar 

  16. Nishida M, Murakawa T, Kamimura T, Okada N (1978) Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Antimicrob Agents Chemother 14:6–12

    Google Scholar 

  17. Vogelman B, Craig WA (1986) Kinetics of antimicrobial activity. J Pediatr 108:835–840

    Google Scholar 

  18. Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F, Glupczynski Y (1987) A comparative study of the rate of bactericidal activity between netilmicin and piperacillin onEscherichia coli andPseudomonas aeruginosa. Curr Therapeut Res 41:823–827

    Google Scholar 

  19. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054–1060

    Google Scholar 

  20. Bundtzen RW, Gerber AU, Cohn DL, Craig WA (1981) Postantibiotic suppression of bacterial growth. Rev Infect Dis 3:28–37

    Google Scholar 

  21. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93–99

    Google Scholar 

  22. Craig WA, Vogelmann B (1987) The postantibiotic effect. Ann Intern Med 106:900–902

    Google Scholar 

  23. Odenholt I, Holm SE, Cars O (1988) An in vivo model for evaluation of the postantibiotic effect. Scand J Infect Dis 20:97–103

    Google Scholar 

  24. Vogelman B, Gudmundsson S, Turnidge I, Leggett J, Craig WA (1988) In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157:287–298

    Google Scholar 

  25. Craig W (1984) Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol 3:575–578

    Google Scholar 

  26. Daenen S, de Vries-Hospers H (1988) Cure ofPseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet I:937

    Google Scholar 

  27. David TJ, Devlin J (1989) Continuous infusion of ceftazidime in cystic fibrosis. Lancet I:1454–1455

    Google Scholar 

  28. Kuzemko J, Crawford C (1989) Continuous infusion of ceftazidime in cystic fibrosis. Lancet II:385

    Google Scholar 

  29. Hoepelman IM, Rozenberg-Arska M, Verhoef J (1988) Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet I:1305–1309

    Google Scholar 

  30. Mandell LA, Bergeron MG, Ronald AR, Vega C, Harding G, Saginur R, Feld R, Duperval R, Landis SJ, Miedzinski LJ, Marrie T, Lalonde RG, Brunton JL, Low DE, Van R (1989) Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized double-blind study. J Infect Dis 160:433–441

    Google Scholar 

  31. Smith CR, Petty BG, Hendrix CW, Kernan WN, Garver PL, Fox K, Beamer A, Carbone K, Threlkeld M, Lietman PS (1989) Ceftriaxone compared with cefotaxime for serious bacterial infections. J Infect Dis 160:442–447

    Google Scholar 

  32. Fan ST, Lau WY, Teoh-Chan CH, Lau KF, Mauracher EH (1988) Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole in gangrenous and perforated appendicitis. J Antimicrob Chemother 22:69–74

    Google Scholar 

  33. Sturm AW (1989) Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 159:931–937

    Google Scholar 

  34. Bennet WM, Plamp CE, Gilbert DN, Parker RA, Porter GA (1979) The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 140:576–580

    Google Scholar 

  35. Frame PT, Phair JP, Watakunakorn C, Bannister TWP (1977) Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 135:952–956

    Google Scholar 

  36. Herscovici L, Grise G, Thauvin C, Lemeland JF, Fillastre JP (1988) Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis 20:205–212

    Google Scholar 

  37. Reiner NE, Bloxham DD, Thompson WL (1978) Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 4 [Suppl. A]:85–101

    Google Scholar 

  38. Wood CA, Norton DR, Kohlhepp SJ, Kohnen PW, Porter GA, Houghton DC, Brummett RE, Bennet WM, Gilbert DN (1988) The influence of tobramycin regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 158:13–22

    Google Scholar 

  39. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, Broe ME de (1989) Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 45:22–27

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Microbiology, Erasmus University, P. O. Box 1738, NL-3000 DR, Rotterdam, The Netherlands

    I. A. J. M. Bakker-Woudenberg & R. Roosendaal

Authors
  1. I. A. J. M. Bakker-Woudenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Roosendaal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakker-Woudenberg, I.A.J.M., Roosendaal, R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 16 (Suppl 3), S229–S234 (1990). https://doi.org/10.1007/BF01709706

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01709706

Keywords

Search

Navigation